The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study.
B. You
No relevant relationships to disclose
O. Colomban
No relevant relationships to disclose
M. Heywood
No relevant relationships to disclose
C. Lee
Consultant or Advisory Role - Roche
M. Davy
No relevant relationships to disclose
N. Reed
No relevant relationships to disclose
S. Pignata
Consultant or Advisory Role - Roche; Schering-Plough
Honoraria - Roche; Schering-Plough
R. Fossati
No relevant relationships to disclose
G. Emons
No relevant relationships to disclose
K. L. Rehman
No relevant relationships to disclose
K. D. Steffensen
No relevant relationships to disclose
E. Petru
No relevant relationships to disclose
V. Gebski
No relevant relationships to disclose
A. Burges
No relevant relationships to disclose
N. Tubiana-Matthieu
No relevant relationships to disclose
M. Hansen
No relevant relationships to disclose
P. A. Vasey
No relevant relationships to disclose
U. Denison
No relevant relationships to disclose
P. De Bruyne
No relevant relationships to disclose
A. M. Oza
No relevant relationships to disclose